| Segment Reporting Disclosure [Text Block] |
Note 11 – Segment reporting
The Company has three reportable segments: Products, Clinical
Services and Therapeutics. The Company’s Products segment develops, manufactures, and markets products to research and pharmaceutical
customers. The Clinical Services segment provides diagnostic services to the health care community. The Company’s Therapeutics
segment conducts research and development activities for therapeutic drug candidates. The Company evaluates segment performance
based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Other”
consist of corporate general and administrative costs which are not allocable to the three reportable segments.
Legal and related expenses incurred to defend the Company’s
intellectual property, which may result in settlements recognized in another segment and other general corporate matters are considered
a component of the Other segment. Legal and related expense specific to other segments’ activities have been allocated to
those segments.
Legal settlements, net, represent activities for which royalties
would have been received in the Company’s Products segment. Management of the Company assesses assets on a consolidated basis
only and therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies
of the reportable segments are the same as those described in the summary of significant accounting policies.
The following financial information represents the operating results of the reportable segments of the
Company:
|
Three months ended October 31, 2019 |
|
Clinical
Services
|
|
Products |
|
Therapeutics |
|
Other |
|
Consolidated |
|
| Revenues |
|
$ |
12,780 |
|
$ |
7,427 |
|
|
— |
|
|
— |
|
$ |
20,207 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Operating costs and expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cost of revenues |
|
|
10,975 |
|
|
3,546 |
|
|
— |
|
|
— |
|
|
14,521 |
|
| Research and development |
|
|
350 |
|
|
516 |
|
$ |
188 |
|
|
— |
|
|
1,054 |
|
| Selling, general and administrative |
|
|
6,215 |
|
|
2,757 |
|
|
— |
|
$ |
2,167 |
|
|
11,139 |
|
| Legal and related expenses |
|
|
50 |
|
|
|
|
|
— |
|
|
1,646 |
|
|
1,696 |
|
| Total operating costs and expenses |
|
|
17,590 |
|
|
6,819 |
|
|
188 |
|
|
3,813 |
|
|
28,410 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Operating income (loss) |
|
|
(4,810 |
) |
|
608 |
|
|
(188 |
) |
|
(3,813 |
) |
|
(8,203 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Interest |
|
|
(12 |
) |
|
18 |
|
|
— |
|
|
231 |
|
|
237 |
|
| Other |
|
|
3 |
|
|
(12 |
) |
|
— |
|
|
136 |
|
|
127 |
|
| Foreign exchange loss |
|
|
— |
|
|
191 |
|
|
— |
|
|
— |
|
|
191 |
|
| Income (loss) before income taxes |
|
$ |
(4,819 |
) |
$ |
805 |
|
$ |
(188 |
) |
$ |
(3,446 |
) |
$ |
(7,648 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Depreciation and amortization included above |
|
$ |
409 |
|
$ |
251 |
|
$ |
— |
|
$ |
65 |
|
$ |
725 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based compensation included in above: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Selling, general and administrative |
|
|
34 |
|
|
22 |
|
|
— |
|
|
163 |
|
|
219 |
|
| Total |
|
$ |
34 |
|
$ |
22 |
|
$ |
— |
|
$ |
163 |
|
$ |
219 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Capital expenditures |
|
$ |
147 |
|
$ |
127 |
|
$ |
— |
|
$ |
— |
|
$ |
274 |
|
|
Three months ended October 31, 2018 |
|
Clinical
Services
|
|
Products |
|
Therapeutics |
|
Other |
|
Consolidated |
|
| Revenues |
|
$ |
14,297 |
|
$ |
6,963 |
|
|
— |
|
|
— |
|
$ |
21,260 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Operating costs and expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cost of revenues |
|
|
10,968 |
|
|
3,271 |
|
|
— |
|
|
— |
|
|
14,239 |
|
| Research and development |
|
|
— |
|
|
507 |
|
$ |
221 |
|
|
— |
|
|
728 |
|
| Selling, general and administrative |
|
|
6,060 |
|
|
2,924 |
|
|
— |
|
$ |
1,986 |
|
|
10,970 |
|
| Legal and related expenses |
|
|
36 |
|
|
7 |
|
|
— |
|
|
1,258 |
|
|
1,301 |
|
| Total operating costs and expenses |
|
|
17,064 |
|
|
6,709 |
|
|
221 |
|
|
3,244 |
|
|
27,238 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Operating income (loss) |
|
|
(2,767 |
) |
|
254 |
|
|
(221 |
) |
|
(3,244 |
) |
|
(5,978 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Interest |
|
|
(18 |
) |
|
16 |
|
|
— |
|
|
276 |
|
|
274 |
|
| Other |
|
|
40 |
|
|
4 |
|
|
— |
|
|
3 |
|
|
47 |
|
| Foreign exchange loss |
|
|
— |
|
|
(324 |
) |
|
— |
|
|
— |
|
|
(324 |
) |
| Loss before income taxes |
|
$ |
(2,745 |
) |
$ |
(50 |
) |
$ |
(221 |
) |
$ |
(2,965 |
) |
$ |
(5,981 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Depreciation and amortization included above |
|
$ |
403 |
|
$ |
342 |
|
$ |
— |
|
$ |
21 |
|
$ |
766 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based compensation included in above: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Selling, general and administrative |
|
|
38 |
|
$ |
24 |
|
|
— |
|
$ |
173 |
|
|
235 |
|
| Total |
|
$ |
38 |
|
$ |
24 |
|
$ |
— |
|
$ |
173 |
|
$ |
235 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Capital expenditures |
|
$ |
354 |
|
$ |
52 |
|
$ |
— |
|
$ |
— |
|
$ |
406 |
|
|